Drugs / Pegfilgastrim
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02505893 | Apr 2015 → May 2018 | type 1 diabetes mellitus | Ospedale San Raffaele | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03036488 Background | Mar 2017 → Oct 2025 | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegfilgastrim | “Neulasta® (pegfilgastrim)” NCT02505893 ↗ |
| Known as | Neulasta | “Neulasta® (pegfilgastrim)” NCT02505893 ↗ |
| Route | Subcutaneous | “Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion” NCT02505893 ↗ |